News First human trial backs AI-designed 'universal' vaccine An AI-powered universal vaccine tech developed by UK biotech DIOSynVax has shown preliminary efficacy in a world-first human trial.
News Moderna's Q1 revenues rocket, thanks to ex-US sales Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.
News Moderna agrees $950m settlement of mRNA jab litigation Moderna's settlement of patent litigation with Arbutus and Genevant over technology used in its Spikevax COVID vaccine could reach up to $2.25bn.
News Moderna closes on EU approval for combined flu/COVID jab Moderna's combined vaccine for both flu and COVID-19 has been recommended for approval in the EU, after being knocked back in the US.
News Bayer's Monsanto sues mRNA COVID-19 vaccine makers Lawsuits filed by Bayer in the US are seeking damages and royalties on sales of COVID-19 shots sold by Pfizer/BioNTech, Moderna, and J&J.
News Investor seeks sale of Novavax after poor COVID jab sales Investor Shah Capital has called on Novavax's board to put the company up for sale, citing a "litany of missteps" at the vaccine developer.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
